Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Expensive Performer
2799.6000 6.90 (0.25%)
NSE May 16, 2025 15:31 PM
Volume: 121.7K
 

2799.60
0.25%
Karvy
Strong growth and margin expansion in Q2FY17 on YoY basis: The company has grown into a national level lab with a hub-and-spoke model, that handled 15.5 Mn samples in H1FY17. On an average 7.04 Mn patients are depending on DLPL for the trusted accurate results. Post monsoon period,seasonal vector bound fevers like malaria, dengue, chikungunya contributed 2% to the volume growth and 3% to the revenue during the quarter. DLPL posted agood revenue growth of 21.5% YoY to Rs.2622 Mn in Q2FY17.
Dr. Lal Pathlabs Ltd. is trading below its 150 day SMA of 2857.7
More from Dr. Lal Pathlabs Ltd.
Recommended